Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,021 to 1,040 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors. | Biomark Res | 2022 | 35658948 | PubTator, text mining | PubMed |
| PPM1D in Solid and Hematologic Malignancies: Friend and Foe? | Mol Cancer Res | 2022 | 35657598 | PubTator, text mining | PubMed |
| Somatic non-cancerous overgrowth syndrome of obscure molecular etiology: what are the causes and options? | J Mol Med (Berl) | 2022 | 35657398 | PubTator, text mining | PubMed |
| Germline genetics of prostate cancer. | Prostate | 2022 | 35657157 | PubTator, text mining | PubMed |
| Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations. | Cancer Epidemiol Biomarkers Prev | 2022 | 35654374 | PubTator, text mining | PubMed |
| BARD1 mystery: tumor suppressors are cancer susceptibility genes. | BMC Cancer | 2022 | 35650591 | PubTator, text mining | PubMed |
| Molecular Subtyping of Cancer Based on Robust Graph Neural Network and Multi-Omics Data Integration. | Front Genet | 2022 | 35646077 | PubTator, text mining | PubMed |
| PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells. | Cell Death Dis | 2022 | 35643812 | PubTator, text mining | PubMed |
| Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. | BMC Cancer | 2022 | 35643464 | PubTator, text mining | PubMed |
| Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. | Int J Oncol | 2022 | 35642662 | PubTator, text mining | PubMed |
| The Existence of at Least Three Genomic Signature Patterns and at Least Seven Subtypes of COVID-19 and the End of the Disease. | Vaccines (Basel) | 2022 | 35632517 | PubTator, text mining | PubMed |
| The Role of DNA Repair in Genomic Instability of Multiple Myeloma. | Int J Mol Sci | 2022 | 35628498 | PubTator, text mining | PubMed |
| Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. | Diagnostics (Basel) | 2022 | 35626184 | PubTator, text mining | PubMed |
| Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition? | Cancers (Basel) | 2022 | 35626165 | PubTator, text mining | PubMed |
| Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. | Cancers (Basel) | 2022 | 35626108 | PubTator, text mining | PubMed |
| Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. | Cancers (Basel) | 2022 | 35626031 | PubTator, text mining | PubMed |
| OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma. | Biomedicines | 2022 | 35625944 | PubTator, text mining | PubMed |
| The Effect of α-Mangostin and Cisplatin on Ovarian Cancer Cells and the Microenvironment. | Biomedicines | 2022 | 35625852 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer. | Biomedicines | 2022 | 35625741 | PubTator, text mining | PubMed |
| A truncating variant of RAD51B associated with primary ovarian insufficiency provides insights into its meiotic and somatic functions. | Cell Death Differ | 2022 | 35624308 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=52